InSilicoTrials

We're thrilled to share that 𝐈𝐧𝐒𝐢𝐥𝐢𝐜𝐨𝐓𝐫𝐢𝐚𝐥𝐬 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚𝐭𝐭𝐞𝐧𝐝𝐢𝐧𝐠 BioTechX, the premier digital transformation event for precision medicine, happening on 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟏𝟕-𝟏𝟖 𝐢𝐧 𝐏𝐡𝐢𝐥𝐚𝐝𝐞𝐥𝐩𝐡𝐢𝐚! This event brings together top leaders from biotech, pharma, fast-growing start-ups, and established solution providers to share insights on the future direction of the industry. Don’t miss the chance to meet our colleague Sofia Stathopoulos and learn about our cutting-edge innovations that are pushing the boundaries of drug development. It’s a great opportunity to connect, collaborate, and explore how we can drive healthcare breakthroughs together. We look forward to engaging with fellow industry leaders at BioTechX, fostering partnerships that will help reshape the future of drug development. #BioTechXUSA #PrecisionMedicine #DigitalHealth #GeneTherapy #DataInnovation

𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀' 𝗖𝗘𝗢 𝗮𝘁 𝗜 𝗮𝗺 𝗕𝗶𝗼 𝗽𝗼𝗱𝗰𝗮𝘀𝘁 - 𝗕𝗜𝗢 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝟮𝟬𝟮𝟰   Last June, our CEO Luca Emili joined the 𝙄 𝙖𝙢 𝘽𝙞𝙤 podcast at BIO International Convention 2024 to discuss how #biotech is paving the way for innovations that benefit both #patients and the #planet. 🌍   𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 is transforming #clinicaltrials with our cutting-edge data platform: merging traditional methods with advanced #simulations, we’re helping companies save up to $30M. An example: our partnership with Axoltis Pharma reduced their #drugdevelopment timeline by 3 years, with $20M potential savings in the process!   We're strongly committed to the democratization of #insilicotechnologies and work to contribute to the uptake of #GoodSimulationPractice: (our CEO co-edited the 𝙏𝙤𝙬𝙖𝙧𝙙 𝙂𝙤𝙤𝙙 𝙎𝙞𝙢𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚 open access book published by Nature Springer: https://lnkd.in/d8ch_7Ys)   ❓ Want to know more about how we're shaping the future of clinical trials? 🎧 Tune in to the #IamBio podcast & get in touch at [email protected] https://lnkd.in/dAa9v8_6 #BIO2024 #iambiopodcast #AI #drugdevelopment #healthcareinnovation #insilico

📣 𝐖𝐞’𝐫𝐞 𝐡𝐢𝐫𝐢𝐧𝐠! 📣 Are you a Senior Pharmacometrician with a passion for creativity and innovation? Join our dynamic team and contribute to cutting-edge consulting and clinical trial simulation projects! #Hiring #Pharmacometrician #ClinicalTrials #Innovation #JobOpportunity

𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗮𝘁 𝗩𝗣𝗛 𝟮𝟬𝟮𝟰 We’re heading to the #VPH2024 Conference in Stuttgart, an event that will showcase cutting-edge, data-driven #simulation technologies revolutionizing #clinical decision-making. Don't miss our oral presentations: ✅ Alessia Baretta will present "𝘕𝘦𝘹𝘵 𝘎𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘊𝘢𝘳𝘥𝘪𝘢𝘤 𝘊𝘢𝘳𝘦: 𝘛𝘩𝘦 SimCardioTest EU project eHealth_EU 𝘊𝘭𝘰𝘶𝘥-𝘉𝘢𝘴𝘦𝘥 𝘗𝘭𝘢𝘵𝘧𝘰𝘳𝘮" (Sept 4, 4:30-4:45 PM). ✅ Vincenzo Carbone, PhD will speak on "𝘛𝘰𝘸𝘢𝘳𝘥 𝘎𝘰𝘰𝘥 𝘚𝘪𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘦: 𝘉𝘦𝘴𝘵 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘦𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘜𝘴𝘦 𝘰𝘧 𝘊𝘰𝘮𝘱𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘔𝘰𝘥𝘦𝘭𝘪𝘯𝘨 𝘢𝘯𝘥 𝘚𝘪𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘵𝘩𝘦 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘗𝘳𝘰𝘤𝘦𝘴𝘴 𝘰𝘧 𝘉𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘗𝘳𝘰𝘥𝘶𝘤𝘵𝘴" (Sept 5, 4:15-4:30 PM). We’re also participating in the 𝗣𝗿𝗲-𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽𝘀 on September 3, including the Final Meeting of the In Silico World Project and Avicenna Alliance Days, where our CEO Luca Emili will discuss "𝘎𝘰𝘰𝘥 𝘚𝘪𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘦𝘴 𝘔𝘰𝘷𝘪𝘯𝘨 𝘛𝘰𝘸𝘢𝘳𝘥 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘊𝘰𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘪𝘰𝘯𝘢𝘭 𝘈𝘐" ℹ https://lnkd.in/eB-iSXGb #AI #insilico #insilicomedicine #constitutionalAI #modelingandsimulation #VPH2024 #InSilicoWorld #AvicennaDays #HealthcareInnovation

We are excited to take part in the 𝗗𝗣𝗛𝗔𝗥𝗠 𝗜𝗱𝗼𝗹 𝗗𝗶𝘀𝗿𝘂𝗽𝘁 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝗼𝗻, where our Chief Operating Officer Mario Torchia will present our innovative #insilico technology to a panel of judges from #pharma #investment, and Patient Advocacy Groups. 📅 Sep 17 - Sep 18, 2024 | Philadelphia, PA The 𝟭𝟰𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗗𝗣𝗛𝗔𝗥𝗠® 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 brings together senior clinical operations executives and thought leaders to discuss the latest advancements in modernizing #clinicaltrials, with a focus on increasing #inclusivity and delivering greater value to #patients. #DPHARM #Innovation #ClinicalResearch #PatientAdvocacy #ClinicalTrials

𝗔𝘀 𝘄𝗲 𝗲𝗺𝗯𝗿𝗮𝗰𝗲 𝘁𝗵𝗲 𝘄𝗮𝗿𝗺𝘁𝗵 𝗼𝗳 𝘀𝘂𝗺𝗺𝗲𝗿, 𝗶𝘁'𝘀 𝘁𝗶𝗺𝗲 𝗳𝗼𝗿 𝗮 𝘄𝗲𝗹𝗹-𝗱𝗲𝘀𝗲𝗿𝘃𝗲𝗱 𝗯𝗿𝗲𝗮𝗸! Our team at InSilicoTrials will be taking some time off to recharge and come back with fresh energy and innovative ideas. We're excited about the future and the continued evolution of our work in 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 technology. 𝗦𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 𝘂𝗽𝗱𝗮𝘁𝗲𝘀, 𝗮𝘀 𝘄𝗲 𝗿𝗲𝘁𝘂𝗿𝗻 𝗿𝗲𝗳𝗿𝗲𝘀𝗵𝗲𝗱 𝗮𝗻𝗱 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗼𝗻 𝗻𝗲𝘄 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗮𝗻𝗱 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀. Looking for some engaging summer reading? Check out 𝗚𝗼𝗼𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 (𝗚𝗦𝗣), a book we co-edited on standardizing simulation practices. It’s a must-read for anyone interested in the credibility and advancement of 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 models in drug development. Discover more about GSP here: https://lnkd.in/d8ch_7Ys Wishing everyone a fantastic summer! 🌴

𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁: 𝗙𝗗𝗔 𝗮𝗻𝗱 𝙄𝙣 𝙎𝙞𝙡𝙞𝙘𝙤 𝗧𝗿𝗶𝗮𝗹𝘀 The FDA is setting new standards in drug development with 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 trials, and we're proud to be at the forefront of this revolution! Luca Emili, CEO of InSilicoTrials, recently shared key insights during a workshop co-hosted by the FDA and the Clinical Trial Transformation Initiative (CTTI): • 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: The FDA is advancing AI Regulatory Science to streamline drug development, with over 300 AI-based submissions under review. • 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆: Luca emphasized how integrating AI with traditional modeling, including virtual patients, reduces costs, speeds up trials, and addresses ethical concerns. • 𝗠𝗼𝗱𝗲𝗹 𝗧𝗿𝘂𝘀𝘁, 𝗧𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆, 𝗮𝗻𝗱 𝗘𝘅𝗽𝗹𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆: 𝘐𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 models must be transparent and explainable to gain trust and ensure their effectiveness. Luca discussed the importance of making AI models not just perform well, but also understandable and interpretable, so stakeholders can confidently rely on them for critical decisions. • 𝗚𝗼𝗼𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 (𝗚𝗦𝗣): The adoption of the GSP framework, as highlighted by Luca, is crucial for standardizing simulation practices and ensuring the credibility and trustworthiness of in silico models in drug development. Discover more about GSP here: https://lnkd.in/d8ch_7Ys • 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗮𝗻𝗱 𝗘𝘁𝗵𝗶𝗰𝗮𝗹 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: By minimizing the need for real patient data and animal testing, 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 trials are making drug development more accessible and ethical. For those invested in the future of healthcare, this article is a must-read. We're excited to see how the work led by Luca and our team at InSilicoTrials is helping shape the future of personalized and innovative treatments! 🌟 #InSilicoTrials #DrugDevelopment #AIinHealthcare #HealthcareInnovation #RegulatoryScience #ClinicalTrials #DigitalHealth #FDA #AI #VirtualPatients #EthicalInnovation #HealthcareRevolution

𝗙𝗗𝗔 𝗖𝗧𝗧𝗜 𝗔𝗜 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽: 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗔𝗜 𝗮𝗻𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻: 𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗶𝘀 𝗡𝗼𝘄 🌐At InSilicoTrials, we are 𝗿𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗯𝘆 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗻𝗴 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗔𝗜 𝘄𝗶𝘁𝗵 𝗿𝗼𝗯𝘂𝘀𝘁 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗺𝗼𝗱𝗲𝗹𝘀 𝗮𝗻𝗱 𝘃𝗶𝗿𝘁𝘂𝗮𝗹 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀. Our CEO and Founder, Luca Emili was invited to speak on a panel with Michael Lingzhi Li (Harvard Business School) and Subha Madhavan (Pfizer). Luca shared the In Silico approach combining a rich library of validated models, an ecosystem of 70 partners, and AI that accelerates data strategies while adhering to Good Simulation Practices (GSP). 📗 𝗚𝗼𝗼𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 (𝗚𝗦𝗣):Co-published as a best practice framework for in silico methods, GSP is the cornerstone of reliable, transparent, and explainable use of simulation in drug development. During the discussion there was many citation to the book that alongside the GMLP is going to support effort in this field and forge the next generation of tech bio scientists. Developed in collaboration with IST, the FDA, VPHi, In Silico World, Avicenna Alliance and over 130 academic and industry experts, this framework turns policy into practice, ensuring that use of simulation in R&D is not only innovative but also safe and trustworthy. Download your free copy ▶ https://lnkd.in/d8ch_7Ys ✨ 𝗔𝗜 𝗶𝗻 𝗔𝗰𝘁𝗶𝗼𝗻 We're excited to present our latest use case, which leverages AI to accelerate the FDA Diversity Action Plan. By automating literature review, we reduce months of work to mere minutes, paving the way for more inclusive and efficient drug development processes. 🔍 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 "𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗜”:This new term encapsulates the essence of model explainability, reliability, and transparency. It’s about building confidence in AI that meets medical-grade standards, offering clear guidance on expected outcomes and ensuring ethical and economic considerations are at the forefront. 𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗶𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗳𝗼𝗿𝗲𝗳𝗿𝗼𝗻𝘁 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻, 𝗿𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝗲𝗱 𝗳𝗼𝗿 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗯𝘆 𝗗𝗲𝘀𝗶𝗴𝗻 𝗯𝘆 𝟵𝟬%. With our trusted AI models, we’re entering a new era of safer drug development.   Join us on this journey to a future where AI-driven innovation ensures better patient outcomes, faster development timelines, and greater confidence in every step of the process. 🌐   #AIinHealthcare #GoodSimulationPractice #DrugDevelopment #InSilicoTrials #MedicalAI #ClinicalResearch #Innovation

As we approach the summer break, we're thrilled to share some 𝐤𝐞𝐲 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐉𝐮𝐥𝐲 𝟐𝟎𝟐𝟒 In Silico World 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 — a project we are part of:  🔸 The 𝐈𝐧 𝐒𝐢𝐥𝐢𝐜𝐨 𝐖𝐨𝐫𝐥𝐝 𝐅𝐢𝐧𝐚𝐥 𝐄𝐯𝐞𝐧𝐭 will take place at VPH2024 in Stuttgart from September 4-6.  🔸 The “𝐓𝐨𝐰𝐚𝐫𝐝 𝐆𝐨𝐨𝐝 𝐒𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐏𝐫𝐚𝐜𝐭𝐢𝐜𝐞” book is now freely available to the entire in silico medicine community.   🔸 Don’t miss 𝐕𝐏𝐇𝟐𝟎𝟐𝟒 — where scientific excellence and collaboration take center stage.   👇 Stay connected and explore more about In Silico World Consortium by clicking the link below! https://bit.ly/3WJbGuD #InSilicoWorld #newsletter #InSilicoTrials #healthcareinnovation #healthcare #insilico #modelingandsimulation

Reminder: Today is the day! The hybrid public workshop on 𝘼𝙧𝙩𝙞𝙛𝙞𝙘𝙞𝙖𝙡 𝙄𝙣𝙩𝙚𝙡𝙡𝙞𝙜𝙚𝙣𝙘𝙚 𝙞𝙣 𝘿𝙧𝙪𝙜 & 𝘽𝙞𝙤𝙡𝙤𝙜𝙞𝙘𝙖𝙡 𝙋𝙧𝙤𝙙𝙪𝙘𝙩 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩, hosted by the FDA and Clinical Trials Transformation Initiative (CTTI), starts at 10 AM EDT (4 PM CET). Our CEO, Luca Emili, will be discussing 𝙈𝙤𝙙𝙚𝙡 𝙋𝙚𝙧𝙛𝙤𝙧𝙢𝙖𝙣𝙘𝙚, 𝙀𝙭𝙥𝙡𝙖𝙞𝙣𝙖𝙗𝙞𝙡𝙞𝙩𝙮, 𝙖𝙣𝙙 𝙏𝙧𝙖𝙣𝙨𝙥𝙖𝙧𝙚𝙣𝙘𝙮 in Session 3. It's a great opportunity to gain insights from leading experts and explore the future of #AI in #drugdevelopment. ✍ Registration is still open: https://lnkd.in/ecWC8iAF